Background {#s1}
==========

Palpitations, presyncope and syncope are potentially debilitating symptoms that can have a significant functional impact on patients. We present an unusual case of these symptoms that were inducible with a simple deep breath, which after extensive investigation was refractory to traditional treatments. These were successfully treated with the centrally acting sympatholytic, clonidine.

Case presentation {#s2}
=================

A 26-year-old man presented to our tertiary syncope centre following previous investigation and treatment elsewhere with daily palpitations, shortness of breath, sweating, presyncope and syncope. Onset of his symptoms followed several weeks of a severe cough and viral respiratory illness 4 years previously. His symptoms were induced on deep respiration or on minimal exertion and showed a diurnal variation, being more pronounced in the early morning and evening, and were not reproducibly related to postural changes. He had over 30 attendances in a year to his local emergency department and had been forced to stop work due to his debilitating symptoms.

Investigations {#s3}
==============

Transthoracic echocardiography was normal, and an electrophysiological study showed suprahisian block with Mobitz type II block interval. There was no evidence of dual AV node physiology, accessory pathway or inducible supraventricular tachycardia.

A subsequent permanent pacemaker led to no further episodes of frank syncope. However his ongoing debilitating exertional and respiratory-driven palpitations with presyncope remained. Conservative measures including increased fluid intake and compression stockings had no effect. Trials of medication including fludrocortisone, flecainide, β blockers and ivabradine were either not tolerated or had no significant effect on his symptoms.

During a simple active stand over 3 min, his heart rate increased from 90 to 112 bpm. His 12 lead ECG at 30° head-up tilt is shown in [figure 1](#BCR2016216818F1){ref-type="fig"} with an initial heart rate of 91 bpm. Following deep inspiration (arrow), his heart rate rapidly increased to 150 bpm within 6 s with no change in P wave or QRS morphology. Maximal heart rate with deep inspiration alone was 167 bpm. Coughing, isometric hand exercise and passive leg raises all led to similar increases in heart rate and reproduction of symptoms despite taking ivabradine 5 mg two times a day.

![12 lead ECG at 30° head up tilt, initially at 91 bpm. Deep inspiration (arrows, left) is followed by an increase in heart rate to 150 bpm within seconds.](bcr-2016-216818f01){#BCR2016216818F1}

Outcome and follow-up {#s4}
=====================

He was started on clonidine 0.1 mg two times a day in combination with ivabradine. This led to a rapid resolution of his respiratory-induced palpitations at rest with no further admissions to hospital. Notably, his quality of life improved sufficiently to allow him to return to work and complete his university degree. Although initially troubled by side effects of drowsiness and fatigue leading to temporary discontinuation of treatment, he has since been re-established on therapy and continues to see benefits from clonidine over 2 years later.

Discussion {#s5}
==========

Variation in heart rate with the respiratory cycle is a well described, but not yet a fully understood phenomenon known as respiratory sinus arrhythmia. Through a predominantly vagally mediated response, the normal response to inspiration is an increase in heart rate. Suggested mechanisms for this response include the activation of pulmonary stretch receptors, increased firing of atrial and arterial baroreceptors and modulation by central respiratory drive.[@R1]

Treatments acting on the efferent end points of this pathway alone, such as ivabradine and β blockers, failed to show any improvement. However, we were able to achieve an excellent response by combining these therapies with the centrally acting clonidine.

###### Patient\'s perspective

Email from the patient (31 October 2016): This condition is far from what I would wish on anyone. However, I have managed to cope with it, as much as can be expected. I still am on clonidine and have been titrated down to 50 µg three times a day. This is one of the tablets that I felt helps me as it stops the forceful contractions of my heart. I find that exercise is still a very big no-no for me. However, I am managing to do everyday things like go to university. Since I last came down to London, this condition has flourished and affected my sleep. It seems like I am using medication to compensate for a switch from parasympathetic to sympathetic state and the reverse (especially at night). Clonidine is one of the tablets that has the least effect on my blood pressure but stops the 'adrenal storms' I usually get. To be honest, I find that the medication I am on only suppresses symptoms and I normally have to prepare for a couple of days of breakthrough symptoms that last longer than if I was not on medication. However, I would prefer to have it this way as it allows me to gain a bit of control over my life. I thank your team for everything they did as you were 100% right in your diagnosis.

###### Learning points

-   Respiratory sinus arrhythmia remains a not yet fully understood mechanism where the respiratory cycle leads to variations in the heart rate in sinus rhythm.

-   While an exaggerated respiratory sinus arrhythmia is commonly seen during tilt testing, such a marked symptomatic sinus tachycardia following a single deep breath proved difficult to manage.

-   When traditional peripherally acting treatments for palpitations such as β blockers and ivabradine have failed, we have shown an excellent response with the addition of the centrally acting agent clonidine.
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